secwatch.observer — SEC 8-K summary
======================================

Issuer:     Humacyte, Inc. (HUMA)
CIK:        0001818382
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001818382-23-000160
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Humacyte Q3 net loss $26M; positive V005 trauma trial results, BLA filing planned this quarter
--------------------------------------------------------------------------------

- Cash and equivalents $100M; funding from Oberland up to $160M, $40M received.
- Net loss $26.0M Q3 2023 vs $25.3M Q3 2022; R&D expenses $18.6M.
- V005 Phase 2/3 trial: 30-day patency 90.2%, amputation rate 9.8%, infection rate 2.0% (vs historic synthetic benchmarks).
- BLA for HAV in vascular trauma planned for FDA filing in Q4 2023.
- Ukraine humanitarian program: 30-day patency 95%, limb salvage and survival 100%, zero infections.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818382/000181838223000160/0001818382-23-000160-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818382/000181838223000160/huma-20231109.htm
  HTML page:      https://secwatch.observer/filing/0001818382-23-000160

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer